Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, genomics, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Biological Processes, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Fundamental Science, Translational Research, Clinical Practice (Health Services and Quality), epidemiology, Clinical Research, genomics, health outcomes research, Diversity, Equity, and Inclusion (DEI) , Chronic Myeloid Malignancies, Diseases, Therapies, Myeloid Malignancies, Biological Processes, Human
Sunday, December 11, 2022: 4:30 PM-6:00 PM
353-355
(Ernest N. Morial Convention Center)
Moderators:
Alice S. Mims, MD, The Ohio State University Comprehensive Cancer Center
and
Gautam Borthakur, MD, University of Texas MD Anderson Cancer Center, Department of Leukemia
Disclosures:
Mims: Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Other: Data Safety and Monitoring Board; BMS: Membership on an entity's Board of Directors or advisory committees; Ryvu: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Other: Data Safety and Monitoring Board; Zentalis: Membership on an entity's Board of Directors or advisory committees; Genentech: Membership on an entity's Board of Directors or advisory committees.
Studies in this section describe the impact of specific genomic aberrations on prognosis in patients with acute myeloid leukemia.
4:30 PM
4:45 PM
5:00 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH